Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I6T-MC-AMBZ – Mirikizumab for Bowel Urgency in Moderately to Severely Active Ulcerative Colitis
2022-502393-16-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in autoimmune colitis, sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in bowel urgency severity (UNRS) score at Week 12. Started Sep 2023; status: completed.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-502393-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502393-16-00.